Boston scientific announces fda approval for the latest-generation watchman flx™ pro left atrial appendage closure device

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety marlborough, mass. , sept. 6, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has received u.s. food and drug administration approval for the latest-generation watchman flx™ pro left atrial appendage closure (laac) device.
BSX Ratings Summary
BSX Quant Ranking